ACADIA Pharmaceuticals Initiates Phase III Trial of Pimavanserin for Adjunctive Treatment in Patients with SchizophreniaBusiness Wire (press release)According to the American Psychiatric Association, about 30 percent of patients with schizophrenia have inadequat
